
Deemea streamlines clinical imaging research by structuring and analyzing medical imaging data to accelerate clinical studies. It uses proprietary AI and a collaborative copilot platform to perform multi-modal, multi-centric imaging processing and data structuring. The platform is positioned as a digital health B2B SaaS solution for biopharmaceutical and medical device clinical teams, emphasizing security, privacy, and data sovereignty. Deemea integrates AI-driven workflows for data harmonization and analysis across sites while supporting sustainability goals for healthcare facilities. The company targets clinical research teams seeking faster, privacy-preserving imaging data pipelines for drug and device development.

Deemea streamlines clinical imaging research by structuring and analyzing medical imaging data to accelerate clinical studies. It uses proprietary AI and a collaborative copilot platform to perform multi-modal, multi-centric imaging processing and data structuring. The platform is positioned as a digital health B2B SaaS solution for biopharmaceutical and medical device clinical teams, emphasizing security, privacy, and data sovereignty. Deemea integrates AI-driven workflows for data harmonization and analysis across sites while supporting sustainability goals for healthcare facilities. The company targets clinical research teams seeking faster, privacy-preserving imaging data pipelines for drug and device development.
What they do: AI-driven platform to structure, harmonize and analyze medical imaging for multicenter clinical research
Headquarters: Paris, France
Founded: 2020
Customers / market: Biopharmaceutical and medical device clinical research teams and investigator centers across multiple European countries
Recent funding: Seed round announced 2024-06-05
Clinical imaging data management and analysis for multicenter clinical research
2020
Biotechnology
Seed round announced on 2024-06-05; Crunchbase lists five funding events including grants and angel rounds.
“YZR Capital, Karista, Bpifrance, AGORANOV”